Edition:
United States

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

26.02USD
23 Feb 2018
Change (% chg)

$-1.39 (-5.07%)
Prev Close
$27.41
Open
$25.48
Day's High
$26.15
Day's Low
$22.92
Volume
1,646,018
Avg. Vol
311,944
52-wk High
$43.98
52-wk Low
$13.51

Select another date:

Thu, Feb 22 2018

BRIEF-Adamas Q4 Loss Per Share $1.27

* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017

BRIEF-Adamas Announces Proposed Public Offering Of Common Stock

* ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results

BRIEF-Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals

* Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​ Source text (http://bit.ly/2zY2CVE) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​

* Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​ Source text : (http://bit.ly/2lnW6oI) Further company coverage:

BRIEF-Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI

* FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI Source text for Eikon: Further company coverage:

BRIEF-Adamas appoints Mardi C. Dier to its board of directors

* Adamas appoints Mardi C. Dier to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica

* Adamas Pharmaceuticals says ‍on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing

BRIEF-Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​

* Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing ‍​ Source text: [http://bit.ly/2xSxczx] Further company coverage:

Select another date: